Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05140421 · ClinicalTrials.gov registry record · NA

Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program

A NA study of HIV, sponsored by City University of New York.

Active
Registry status
NA
Development phase
1,494
Enrollment target
20
Study locations

NCT05140421 is a NA study of HIV that is active but no longer recruiting, run by City University of New York. The registered enrollment target is 1,494 participants, above the 435-participant average among 303 other HIV trials with a reported enrollment target (243% higher). The trial reports 20 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05140421, a NA study of HIV, is active but no longer recruiting, sponsored by City University of New York.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
1,494 participants
Enrollment target
20
Study locations

Study Summary

The Ryan White HIV/AIDS Program (RWHAP) for low-income people with HIV (PWH) is a key resource for reducing HIV health disparities and scaling up evidence-based interventions. As RWHAP serves \>50% of US PWH, RWHAP outcomes are vital to achieving "getting-to-zero"/ Ending the HIV Epidemic (EHE) Plan targets. As a grantee for RWHAP Part A (RWPA) funding distributed to the counties/cities severely affected by HIV, New York City (NYC) conducts regular HIV care continuum monitoring citywide and in its RWPA programs, which offer support services to reduce social and behavioral barriers to care/treatment. Local data consistently show lower viral suppression (VS) among RWPA clients in HIV care than among non-RWPA PWH in HIV care. Relative to NYC HIV cases overall, NYC RWPA clients (\~14,000 per year) over-represent Black and Latinx PWH and high-poverty neighborhoods. To address local outcome disparities and to fill gaps left by data-to-care strategies and research focused on medical care (re-)linkage, the investigators propose to implement and rigorously evaluate the effectiveness of a novel 'data-to-suppression' (D2S) intervention among RWPA behavioral health and housing program clients who are in HIV care but unsuppressed. Surveillance-based reports on unsuppressed clients plus D2S capacity-building assistance will guide RWPA providers in targeting and delivering evidence-informed strategies to improve VS.

Conditions Studied

Interventions

  • OTHER Data to Suppression (D2S)
  • OTHER Usual practice

Study Locations (20)

New York

  • Alliance for Positive Change - New York
  • Mount Sinai Beth Israel - New York
  • Exponents, Inc. - New York
  • GMHC - New York
  • African Services Committee, Inc. - New York
  • Harlem United - New York
  • New York Presbyterian Hospital - New York
  • Bailey House, Inc. - New York
  • New York Harm Reduction Educators, Inc. - New York
  • The Institute for Family Health - New York
  • NYC Health and Hospitals Harlem - New York
  • Project Hospitality, Inc. - New York
  • Boom!Health - New York
  • BronxWorks, Inc. - New York
  • St. Ann's Corner of Harm Reduction - New York
  • Tolentine Zeiser Community Life Center - New York
  • Housing Works - New York
  • Research Foundation of State University of New York - New York
  • La Nueva Esperanza, Inc. - New York
  • NYC Health and Hospitals Woodhull - New York

Trial Details

FieldValue
Enrollment Target 1,494 participants
Start Date 2021-12-15
Est. Completion 2026-04-30
Phase NA

Sponsor

City University of New York

9 total trials

What the Registry Record Tells You About NCT05140421

The ClinicalTrials.gov registry entry for NCT05140421 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,494 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 435-participant average among 303 other HIV trials with a reported enrollment target (243% higher). The listed sponsor is City University of New York, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Data to Suppression (D2S) is the first listed.

NCT05140421 reports 20 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05140421 about?

NCT05140421 is a clinical study titled "Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program". The Ryan White HIV/AIDS Program (RWHAP) for low-income people with HIV (PWH) is a key resource for reducing HIV health disparities and scaling up evidence-based interventions. As RWHAP serves \>50% of US PWH, RWHAP outcomes are vital to achieving "getting-to-zero"/ Ending the HIV Epidemic (EHE) Plan...

What is the current status of trial NCT05140421?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,494 participants. The study started on 2021-12-15. Estimated completion is 2026-04-30.

What conditions does trial NCT05140421 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT05140421?

The interventions under investigation include: Data to Suppression (D2S) (OTHER), Usual practice (OTHER).

Who is sponsoring clinical trial NCT05140421?

This trial is sponsored by City University of New York, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05140421 being conducted?

This trial has 20 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.